TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Definium Therapeutics reported that its investigational oral LSD formulation, DT120, met the primary endpoints in Phase III trials for generalized anxiety disorder and major depressive disorder. The company reported symptom improvements versus placebo, with effects measured through 12 weeks, but the supplied report does not include full trial publications or a regulatory timeline.
Definium Therapeutics said its investigational oral lysergide (LSD) tablet, DT120, met the primary endpoints in two Phase III trials involving people with generalized anxiety disorder and major depressive disorder. The company reported statistically significant symptom reductions compared with placebo, but DT120 remains investigational and the supplied report does not establish whether it will be submitted for regulatory approval.
In the 214-participant Voyage trial for generalized anxiety disorder, participants received a single supervised 100-microgram dose. At week 12, the DT120 group had an average 11.6-point reduction in HAM-A anxiety scores from baseline; the placebo-adjusted difference was 5.4 points (P<0.0001). The report says a statistically significant difference was present by week 1, when the reduction from baseline was 11.9 points and the difference versus placebo was 7.7 points.
In the 149-participant Emerge trial for major depressive disorder, the primary endpoint was change in MADRS depression scores at week 6. Definium reported an 8.1-point placebo-adjusted improvement at that point (P<0.0001), with a 7.3-point placebo-adjusted difference still present at week 12 (P<0.0001). The report also describes improvements at week 1, but does not provide full trial data or a peer-reviewed publication in the supplied material.
Both studies were presented at the NEI Fall Congress in Colorado Springs, according to the report. Participants received treatment in a supervised session rather than taking DT120 daily. Average time to meet discharge criteria was 6.4 hours in Voyage and 5.8 hours in Emerge; all Emerge participants and 90% of Voyage participants had met the stated criteria by hour eight.
A Single Supervised Dose, Measured Over Weeks
The results could matter because they point to a treatment approach different from daily medication: both trials evaluated one supervised dosing session and tracked symptoms for weeks afterward. That design may be relevant to patients and clinicians seeking alternatives, particularly because the company reported that many participants had previously tried multiple medications.
However, the findings are not evidence that DT120 is approved, broadly effective in routine care, or appropriate for any particular patient. The reported endpoint differences are trial results, and their clinical meaning and durability require scrutiny alongside full methods, safety data and independent review. A supervised session lasting several hours also has practical implications for staffing and access if the approach advances.
Products Worth Considering
Levoit Vital 100S-P Smart Air Purifier with Washable Pre-Filter
Oral-B iO5 Rechargeable Electric Toothbrush with 5 Cleaning Modes and Travel Case, White
Oura Ring 5 Smart Ring, Gold, Size 10
As an affiliate, we earn on qualifying purchases.
What Voyage and Emerge Tested
DT120 is described as an orally disintegrating tablet formulation of lysergide, the psychedelic also known as LSD. Voyage studied adults with generalized anxiety disorder, whose average baseline HAM-A score was 27.9; eligibility required a score of at least 20. Emerge enrolled people with major depressive disorder and an average baseline MADRS score of 34.5, with an active episode lasting from eight weeks to 24 months.
The studies used different primary measures and time points: HAM-A at week 12 for Voyage and MADRS at week 6 for Emerge. The report says placebo-adjusted benefits remained at week 12 in both trials. It also reports higher response and remission rates than placebo on secondary measures. These are company-reported trial findings presented at a medical congress, rather than a full account of the study protocols and results.
“Seeing a clinically meaningful improvement in patients with this level and duration of disease gives us hope that DT120 could offer a new treatment option for people who have been suffering for years and are still in need of better outcomes.”
— Dan Karlin, chief medical officer of Definium Therapeutics, speaking to MedPage Today
Key Trial and Safety Details Still Pending
The supplied report does not provide full trial protocols, detailed participant flow, or complete statistical analyses, and it does not state whether the results have been published in a peer-reviewed journal. It is also unclear from the material whether the trials were designed to compare DT120 with standard treatments; the reported comparator was placebo.
The report characterizes DT120 as generally well tolerated. It says no serious adverse events were reported in either trial; in Emerge, it also reports no suicidal behaviors or discontinuations due to adverse events. Common effects included illusions, euphoric mood and nausea on dosing day, followed by headache. These findings should be read within the studies’ size and observation period: longer-term safety, uncommon harms and outcomes beyond the reported follow-up are not established here.
Also not specified are the companies’ next regulatory steps, the full criteria for selecting patients, or whether any additional studies will be required. Meeting Phase III endpoints does not itself constitute regulatory approval.
Regulatory Plans and Full Data
The next developments to watch are publication of complete Phase III results and any announcement from Definium about discussions with regulators or plans to seek approval. The supplied report gives no timetable for a filing, additional studies, or a possible decision.
Further review would allow clinicians and regulators to examine the trial designs, the size and consistency of the treatment effects, safety monitoring and how long benefits lasted after the single dose. Until those details and any regulatory decisions are available, DT120 remains an investigational treatment.
Key Questions
What is DT120?
DT120 is an investigational orally disintegrating tablet formulation of lysergide, or LSD. In the trials described, it was given as a single dose during a supervised session.
What did the Phase III trials find?
Definium reported that Voyage met its primary endpoint for generalized anxiety disorder, with a 5.4-point placebo-adjusted HAM-A difference at week 12. Emerge met its primary endpoint for major depressive disorder, with an 8.1-point placebo-adjusted MADRS difference at week 6.
Is DT120 approved for anxiety or depression?
No approval is reported. The source describes DT120 as investigational and does not provide a regulatory filing or decision timeline.
How long were participants followed?
The reported study results include follow-up through week 12. The supplied material does not establish how long any benefits or safety findings may persist beyond that period.
What side effects were reported?
The report lists illusions, euphoric mood and nausea as common effects on dosing day, and headache afterward. It says no serious adverse events were reported in either trial, but full safety data and longer-term risks are not provided in the supplied material.
Source: medpagetoday.com
